BioNTech will work with China's Fosun Pharma to commercialize the vaccine — dubbed BNT162 — in China and is in "advanced discussions" with existing partner Pfizer to do the same elsewhere.
So, it’s somewhat surprising to see BNTX up 65% today the official PR.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”